Who controls which cohort, and on what evidence. Drug-by-drug commercial posture, prescribing share and payer positioning.
Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.
Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.
Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window.
Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.
Tirzepatide 20.9% versus semaglutide 15.3% weight loss. The Medicare coverage gap and commercial step-edit reality.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.
From zero disease-specific drugs to five in three years: how endothelin, complement and APRIL inhibitors are redrawing the IgAN market.
The prophylaxis class is fracturing along route: oral berotralstat and the first oral on-demand agent against a still-injectable antibody field.
Tafamidis's ATTR-CM monopoly meets acoramidis — while the orphan-drug exclusion keeps the stabilizer class out of IRA price negotiation.
Three novel mechanisms in 24 months — FcRn antagonists vs C5 inhibitors, and the AChR+ vs MuSK+ line that segments the market.
Two Dec-2023 gene therapies (Casgevy, Lyfgenia) reset a ~100,000-patient market, while voxelotor's 2024 withdrawal thins the oral field.
Two next-generation ERTs, avalglucosidase alfa and cipaglucosidase alfa plus miglustat, move to displace alglucosidase alfa across the US late-onset Pompe market.
Five FDA-approved Gaucher type 1 therapies (three IV enzyme replacement vs two oral substrate reduction) and eliglustat's oral first-line pivot.
Sutimlimab (Enjaymo) is the only FDA-approved CAD therapy — competing against off-label rituximab-based standard of care, not a branded rival.
Three mechanisms, one SMN target — a one-time $2.125M gene therapy versus chronic intrathecal ASO and daily oral, and newborn screening resets the battlefield.
Two IV enzyme replacement therapies meet an oral chaperone that only ~35–50% of patients can take — and pegunigalsidase now challenges Fabrazyme's two-decade lead.
Fenfluramine leads on efficacy, cannabidiol anchors the lower-cost branded option, and stiripentol holds the adjunct niche.
The COPD maintenance fight has moved past the inhaler. Two 2024 approvals, ensifentrine and dupilumab, opened the first genuinely novel mechanisms in a decade and split the market into an inhaler base and a biology-defined add-on tier.
Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US: IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2, and the efficacy bar has moved from PASI 75 to PASI 90.
First-line HR+/HER2- metastatic disease is a three-way CDK4/6-inhibitor contest, but only ribociclib has posted consistent overall-survival wins (63.9 vs 51.4 months in MONALEESA-2, HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.
Tafamidis's ATTR-CM franchise meets acoramidis under NICE — which now tells clinicians to pick the least-expensive stabiliser.
Anti-C5 IV therapy holds the GCC PNH market under NPHC/MOH specialist-centre gating, while iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary.
Novel IgAN agents are newly registered across the GCC but not yet formulary-listed — nephrology specialist centres and the private hospital market are the fastest access channel while biopsy capacity limits diagnosis.
GCC HAE management is acute-only — prophylaxis penetration is near zero, more than 85% of patients are undiagnosed, and NPHC coverage for lanadelumab would be the access trigger for the region's largest market.
Tafamidis is SFDA-registered and tender-priced 80-90% below US list, but ATTR-CM in the GCC is a pre-commercial opportunity gated by Tc-PYP scintigraphy availability at fewer than 8 centres, not by drug access.
GCC Dravet prescribing runs opposite the US/EU hierarchy: cannabidiol is de-facto inaccessible under narcotics law, so stiripentol, not cannabidiol, is the de-facto specialist standard of care.
GCC carries one of the highest per-capita SCD burdens globally: ~140,000 patients in Saudi Arabia alone. Both novel disease-modifiers hit regulatory trouble in 2023-2024, leaving a 25-year-old generic as the only agent with a stable market position.
Nexviazyme beat Lumizyme on 6-minute-walk distance in COMET — but NPHC hasn't set switch criteria, so 80-120 GCC ERT patients mostly stay on the 2006-era standard.
Cannabidiol and fenfluramine anchor the NHS-commissioned NICE algorithm; stiripentol still holds a backbone role. New entrants must beat an entrenched three-drug sequence, not just show efficacy.
Oral migalastat versus IV enzyme replacement, and how pegunigalsidase's newly NICE-recommended suboptimal-responder appraisal (TA915) reshapes NHS-commissioned Fabry therapy.
Efgartigimod reached GCC neurology centres via SFDA/MOH UAE registration in 2023 — but NPHC formulary criteria for the FcRn class don't yet exist, so pyridostigmine and steroids still treat 85%+ of patients.
Crizanlizumab's EMA/MHRA withdrawal leaves a VOC-prevention gap. Casgevy's NICE recommendation is the watershed NHS gene-therapy access event — Lyfgenia has no UK regulatory status.
Avalglucosidase's NICE recommendation (TA821) versus entrenched alglucosidase alfa. NHS switch criteria and the Pombiliti queue position define the next 18 months of UK access.
England's NICE has issued three positive technology appraisals funding HAE prophylaxis since 2019 (TA606, TA738, TA1101), but the two newest MHRA-licensed agents, donidalorsen and sebetralstat, remain in NICE appraisal with no confirmed final NHS funding decision.
All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.
All three SMA mechanisms are formulary-listed in GCC — and outcomes-based rebate contracts now anchor Zolgensma's ~$1.5-1.8M price to a 24-month motor-milestone, following an NBS expansion generating 60-80 new gene-therapy candidates a year.
All three UK PNH agents have cleared NICE via the standard Technology Appraisal route: ravulizumab (TA698), iptacopan (TA1000), and crovalimab. Convenience and switch dynamics, not pathway-driven affordability, now determine NHS share.
Iptacopan's orphan-drug status let it clear AMNOG with an established additional benefit and a substantial quality-of-life finding. Ravulizumab, tested on Germany's only PNH-specific G-BA review to date, found no added benefit at all.
GCC is a two-ERT Fabry market (agalsidase alfa via the EMA pathway alongside agalsidase beta), while migalastat's oral advantage, covering 35-50% of patients, is bottlenecked by the single GCC lab that can run the amenable-mutation assay.
No novel biologic is yet NHS-commissioned for generalised MG. Eculizumab's manufacturer withdrew its 2020 NICE appraisal before a verdict, and NICE rejected efgartigimod outright in 2025 — leaving rozanolixizumab as the FcRn class's last untested NICE bid.
HAS restricted iptacopan to second-line use only, anemic patients with haemoglobin below 10 g/dL after at least six months on an anti-C5 inhibitor, and rated it ASMR III. Ravulizumab holds the first-line position with SMR important.
Two novel agents in Named Patient access ahead of NICE decisions — and the £20,000-30,000/QALY standard threshold both must clear, since IgAN doesn't qualify for the ultra-rare HST track.
A 24–32 page PDF analyst brief, an editable Excel model, and a PowerPoint readout, with a 45-minute analyst call included.
Every figure is cited to a live PMID, ClinicalTrials.gov ID or URL at the point of writing, cross-checked against the source, and re-checked in an independent audit pass.
Yes. Intake captures your indication, comparators, market and the specific commercial question. A scoping call confirms scope before research begins.